Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant
- Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance
- Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance
- Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1 Combination therapy: Current status and future perspectives Manzoor Ahmad Malik, Mohmmad Younus Wani, and Athar Adil Hashmi
2 Combination therapy against multidrug resistance Musa Marimani
3 Multidrug resistance and the prospects of combination therapy A. Balakrishna, G. Sravya, T.V. Surendra, C. Suresh Reddy, Grigory V. Zyryanov, and N. Bakthavatchala Reddy
4 Combination therapy against human infections caused by Candida species Indresh Kumar Maurya, Ruchi Badoni Semwal, and Deepak Kumar Semwal
5 Metallodrug-driven combination chemotherapy in cancer treatment Afzal Hussain, Mohamed Fahad AlAjmi, Prince F. Iqbal, and Waseem A. Wani
6 Combination antituberculosis therapy: Opportunities and challenges to combat drug-resistant tuberculosis Sudarkodi Sukumar, Md. Zafaryab, Md. Khurshid Alam Khan, Krishnan Hajela, and Mohammad Nasiruddin,
7 Synergistic effect of drugs against multiple drug-resistant swine pathogen Streptococcus suis Shama Khan
8 Combination therapy and multidrug resistance in malaria parasite Abdul Hafiz, Mahmood A. Alam, Othman A. Alghamdi, and Arif Mohammed
9 Combination therapy as an effective tool for treatment of drug-resistant viral infections Musa Marimani, Aijaz Ahmad, and Adriano Duse
10 Combination therapy against human infections caused by viruses Rifat Munir
11 Phenotype screenings of drugs for combination therapy against multidrug resistance Arif Mohammed and Othman A. Alghamdi
12 New approaches for targeting drug resistance through drug combination Shailesh Kumar Singh, Arif Mohammed, Othman A. Alghamdi, and Syed Masood Husain
Mohmmad Younus Wani, PhD, Assistant Professor, Department of Chemistry, College of Science, University of Jeddah, Kingdom of Saudi Arabia. Dr. Wani graduated from Jamia Millia Islamia, New Delhi, India in 2013. Received a senior research fellowship from CSIR-India in 2012 and FCT postdoctoral fellowship from Portugal in 2013. Worked as a postdoctoral fellow with Prof. A. Sobral group from 2013-2016 on the development of fungal cell wall targeted antifungal therapies. In fall 2016, Dr. Wani moved to the University of Texas, USA, Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, UTHealth on the development of non-traditional antimicrobial agents and strategies combating multi-drug resistance. He has many international publications, book chapters, and a book, besides many international and national honours and awards to his credit. Dr. Wani is working hard to advance the medicinal chemistry and drug discovery field with new questions and pertinent issues of 21st century.
Aijaz Ahmad, PhD, Lecturer, Department of Clinical Microbiology and Infectious Diseases, University of the
Witwatersrand, Johannesburg, South Africa and Medical Scientist, Division of Infection Control, Charlotte Maxeke Johannesburg Academic Hospital, National Health Laboratory Service (NHLS), Johannesburg, South Africa. Dr. Ahmad has specialties in Infectious Diseases, Clinical Microbiology, Biochemistry, Molecular Biology, and Microbial Pathogenesis. He has been awarded South African National Research Foundation Scientist Rating of Y2 (Promising young researchers) and he is a Lifetime fellow member of Scientific Society of Advanced Research and Social Change, a Fellow member of South African Society of Biochemistry and Molecular Biology and a Committee member of National Health Laboratory Services Research and Development Committee.